GeneDx Holdings (WGS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Daniel Brennan from TD Cowen reiterated a Buy rating on the stock and has a $135.00 price target.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Daniel Brennan has given his Buy rating due to a combination of factors influencing GeneDx Holdings’ positive outlook. The company recently reported significant gains, with its stock closing up by 42% following the release of its full fourth-quarter results and guidance for 2025, which outperformed consensus expectations by 5%. This impressive performance is supported by the anticipated growth in NICU settings, the rollout of new indications, and the evident operating leverage.
In addition, the 2025 guidance, although conservative, suggests further upside potential, particularly as only about 5% of the total addressable market has been penetrated. The company’s earnings and free cash flow are expected to inflect positively, and with continued strong performance projected for 2025, there is room for further gains. The introduction of new testing capabilities in both outpatient and inpatient settings, including the EPIC Aura for NICU and a rapid genome test, is expected to drive growth and command higher average selling prices, reinforcing the Buy rating and increased price target set by Brennan.
According to TipRanks, Brennan is a 5-star analyst with an average return of 13.1% and a 46.67% success rate. Brennan covers the Healthcare sector, focusing on stocks such as Exact Sciences, Revvity, and Natera.
In another report released yesterday, BTIG also maintained a Buy rating on the stock with a $115.00 price target.